Tag Archives: PhRMA

PhRMA Dismayed by Global IPR Report

By Guest Blogger | Published: May 6, 2013
Posted in Global, Guest Blog, IP, Regulatory | Also tagged , , | Leave a comment

PCORI Launches Clinical Research Network to Support Trials, Outcomes Research

By Jill Wechsler | Published: April 30, 2013
The new National Patient-Centered Clinical Research Network funded by the Patient-Centered Outcomes Research Institute (PCORI) aims to provide patients and clinicians with useful information on treatment options and outcomes. By encouraging more comparative clinical effectiveness research (CER),  the program also has potential to support development of new drugs and devices, explained PCORI executive director Joe [...]
Posted in FDA, healthcare | Also tagged , , , , , , , , , , , , , | Leave a comment

Getting it Done in Washington

By Ben Comer | Published: February 13, 2013
During his fifth State of the Union address, President Obama struck many familiar chords – including a line about ending certain subsidies to pharmaceutical companies – and emphasized, repeatedly, the need to get things done on the policy front. Will the sequestration drum beat goad members of the 113th Congress onto the dance floor?
Posted in Legal, R&D, Strategy, healthcare, pricing | Also tagged , , , , , , | Leave a comment

Will "Robust Pipeline" Yield More New Drugs?

By Jill Wechsler | Published: January 21, 2013
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in [...]
Posted in Biotech, FDA, R&D, Regulatory, leadership | Also tagged , , , , , | Leave a comment

Fixing Innovation: Lilly's CEO Says Why, and How

By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Also tagged , , , , , , , , , , , , | 1 Comment